The DOI matches its Crossref record; 538 of the 538 references it cites were found in a registry or an index.
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Abstract
This article reviews the metabolic pharmacokinetic drug-drug interactions with the systemic antifungal agents: the azoles ketoconazole, miconazole, itraconazole and fluconazole, the allylamine terbinafine and the sulfonamide sulfamethoxazole. The majority of these interactions are metabolic and are caused by inhibition of cytochrome P450 (CYP)-mediated hepatic and/or small intestinal metabolism of coadministered drugs. Human liver microsomal studies in vitro, clinical case reports and controlled pharmacokinetic interaction studies in patients or healthy volunteers are reviewed. A brief overview of the CYP system and the contrasting effects of the antifungal agents on the different human drug-metabolising CYP isoforms is followed by discussion of the role of P-glycoprotein in presystemic extraction and the modulation of its function by the antifungal agents. Methods used for in vitro drug interaction studies and in vitro-in vivo scaling are then discussed, with specific emphasis on the azole antifungals. Ketoconazole and itraconazole are potent inhibitors of the major drug-metabolising CYP isoform in humans, CYP3A4. Coadministration of these drugs with CYP3A substrates such as cyclosporin, tacrolimus, alprazolam, triazolam, midazolam, nifedipine, felodipine, simvastatin, lovastatin, vincristine, terfenadine or astemizole can result in clinically significant drug interactions, some of which can be life-threatening. The interactions of ketoconazole with cyclosporin and tacrolimu…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fluconazole is highly soluble in water and binds weakly to plasma proteins [22], whereas lovastatin is lipophilic with high affinity for protein binding [8].”
Citations
Cites
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,665
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
A physiological approach to hepatic drug clearance
Wilkinson, G. R., & Shand, D. G. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975184377 · Cited by 1,873
Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., & Borst, P. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118214 · Cited by 1,107
Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., & Wilkinson, G. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1269 · Cited by 1,054
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Wacher, V. J., Wu, C., & Benet, L. Z. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940130302 · Cited by 857
Human P450 metabolism of warfarin
Kaminsky, L. S., & Zhang, Z.-Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00140-4 · Cited by 798
The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Research works printed but not linked: 131
- Hajek, 1982, J Pharmacol Exp Ther, 223, 97
- Shimada, 1994, J Pharmacol Exp Ther, 270, 414
- Hargreaves, 1994, Br J Clin Pharmacol, 38, 175P
- Lampen, 1995, Drug Metab Dispos, 23, 1315
- Gentile, 1996, J Pharmacol Exp Ther, 277, 105
- Pichard, 1990, Drug Metab Dispos, 18, 595
- Lavrijsen, 1993, Allergy, 48, 34
- Zhou-Pan, 1993, Cancer Res, 53, 5121
- von Moltke, 1994, J Pharmacol Exp Ther, 268, 1278
- von Moltke, 1996, J Pharmacol Exp Ther, 276, 370
- Jurima-Romet, 1994, Drug Metab Dispos, 22, 849
- Nakasa, 1993, Mol Pharmacol, 44, 216
- Bourrie, 1996, J Pharmacol Exp Ther, 277, 321
- Kunze, 1996, Drug Metab Dispos, 24, 414
- Fitzsimmons, 1997, Drug Metab Dispos, 25, 256
- Code, 1997, Drug Metab Dispos, 25, 985
- Erickson, 1997, ISSX Proc, 12, 49
- Heyn, 1996, Drug Metab Dispos, 24, 948
- Ko, 1998, Drug Metab Dispos, 26, 775
- Chang, 1993, Cancer Res, 53, 5629
- Hall, 1987, J Pharmacol Exp Ther, 240, 216
- Wienkers, 1996, Drug Metab Dispos, 24, 610
- Leeder, 1998, Clin Pharmacol Ther, 63, 216
- Newton, 1995, Drug Metab Dispos, 23, 154
- von Moltke, 1998, Pharm Pharmacol Commun, 4, 443
- Schuetz, 1996, Mol Pharmacol, 49, 311
- Schinkel, 1998, Int J Clin Pharmacol Ther, 36, 9
- Schmider, 1995, J Pharmacol Exp Ther, 275, 592
- Obach, 1996, Drug Metab Dispos, 24, 1047
- Obach, 1997, Drug Metab Dispos, 25, 1359
- Black, 1996, Drug Metab Dispos, 24, 422
- Ring, 1995, J Pharmacol Exp Ther, 275, 1131
- Kunze, 1996, Drug Metab Dispos, 24, 429
- Ervine, 1996, Drug Metab Dispos, 24, 211
- Olkkola, 1996, Anesth Analg, 82, 511
- Negroni, 1993, Arch Med Res, 24, 387
- Gomez, 1994, Clin Pharmacol Ther, 55, 209
- Albengres, 1992, Int J Clin Pharmacol Ther Toxicol, 30, 555
- Canafax, 1991, Transplant Proc, 23, 1041
- Butman, 1991, J Heart Lung Transplant, 10, 351
- First, 1993, Transplant Proc, 25, 591
- Sorenson, 1994, Transplant Proc, 26, 2822
- Odocha, 1996, Transplant Proc, 28, 907
- Schroeder, 1987, J Heart Transplant, 6, 84
- Karlix, 1993, Transplantation, 56, 1554
- Pichard, 1990, Drug Metab Dispos, 18, 711
- Horton, 1992, J Heart Lung Transplant, 11, 1127
- Lo, 1997, Br J Clin Pharmacol, 43, 340
- Karanam, 1994, Drug Metab Dispos, 22, 811
- Sattler, 1992, Drug Metab Dispos, 20, 753
- Iwasaki, 1993, Res Commun Chem Pathol Pharmacol, 82, 209
- Assan, 1994, Diabete Metab, 20, 49
- Vanakoski, 1995, Int J Clin Pharmacol Ther, 33, 518
- Kronbach, 1989, Mol Pharmacol, 36, 89
- Pichard, 1995, Drug Metab Dispos, 23, 1253
- Koyama, 1997, J Pharmacol Exp Ther, 281, 1199
- Nielsen, 1996, J Pharmacol Exp Ther, 277, 1659
- Rotzinger, 1998, Drug Metab Dispos, 26, 572
- Pirmohamed, 1995, J Pharmacol Exp Ther, 272, 984
- Linnet, 1997, Drug Metab Dispos, 25, 1379
- Bajpai, 1996, Drug Metab Dispos, 24, 1401
- Molholm Hansen, 1975, BMJ, 2, 684
- Yun, 1993, Drug Metab Dispos, 21, 403
- Ling, 1995, Drug Metab Dispos, 23, 631
- Rodrigues, 1995, Drug Metab Dispos, 23, 765
- Kuang, 1994, Clin Pharmacol Ther, 55, 139
- Kuang, 1995, Clin Pharmacol Ther, 57, 185
- Kuang, 1995, Clin Pharmacol Ther, 57, 185
- Paserchia, 1994, Clin Pharmacol Ther, 55, 146
- Eller, 1991, Clin Pharmacol Ther, 49, 130
- Cantilena, 1995, Clin Pharmacol Ther, 57, 185
- Tsai, 1997, J Formosan Med Assoc, 96, 144
- Van Peer, 1993, Allergy, 48, 34
- Brannan, 1995, Clin Pharmacol Ther, 57, 193
- Linthoudt, 1996, J Heart Lung Transplant, 15, 1165
- Ludwig, 1989, Drug Intell Clin Pharm, 23, 858
- Jonsson, 1995, Drug Metab Dispos, 23, 137
- Guengerich, 1988, Mol Pharmacol, 33, 500
- Pillans, 1993, NZ Med J, 106, 436
- Meyboom, 1997, NZ Med J, 110, 300
- Kovacs, 1986, Ther Hung, 34, 167
- Swinney, 1990, Drug Metab Dispos, 18, 859
- Seaton, 1990, Drug Intell Clin Pharm, 24, 1177
- Pillans, 1996, NZ Med J, 109, 346
- Kazmier, 1976, Mayo Clin Proc, 51, 782
- Errick, 1978, Am J Hosp Pharm, 35, 1399
- Greenlaw, 1979, Am J Hosp Pharm, 36, 1155
- Cook, 1994, J Fam Pract, 39, 589
- Sharer, 1996, Drug Metab Dispos, 24, 487
- Blyden, 1986, Int J Clin Pharmacol Ther Toxicol, 24, 225
- Purba, 1986, Br J Clin Pharmacol, 21, 603P
- Brockmeyer, 1997, Eur J Med Res, 2, 377
- Tjia, 1996, J Pharmacol Exp Ther, 276, 912
- Murphy, 1987, Ir Med J, 80, 123
- Nix, 1992, Clin Pharmacol Ther, 51, 183
- Reitberg, 1983, Clin Pharm, 2, 441
- Kovacs, 1999, Clin Pharmacol Ther, 65, 132
- Kroemer, 1992, J Pharmacol Exp Ther, 260, 1052
- Fabre, 1993, Drug Metab Dispos, 21, 978
- Guengerich, 1986, Mol Pharmacol, 30, 287
- Funck-Brentano, 1989, J Pharmacol Exp Ther, 249, 134
- McNulty, 1989, Clin Pharm, 8, 222
- Abolfathi, 1995, Clin Pharmacol Ther, 57, 215
- Cone, 1996, West J Med, 165, 322
- Prueksaritanont, 1997, Drug Metab Dispos, 25, 1191
- Stearns, 1995, Drug Metab Dispos, 23, 207
- Otton, 1988, J Pharmacol Exp Ther, 247, 242
- Masubuchi, 1994, Drug Metab Dispos, 22, 909
- Oldham, 1997, Drug Metab Dispos, 25, 970
- Cribb, 1995, Drug Metab Dispos, 23, 406
- Zhao, 1996, J Pharmacol Exp Ther, 279, 1327
- Zhao, 1997, Drug Metab Dispos, 26, 188
- Muindi, 1993, Cancer Res, 53, 1226
- Buggia, 1996, Anticancer Res, 16, 2083
- Rahman, 1994, Cancer Res, 54, 5543
- Cresteil, 1994, Cancer Res, 54, 386
- Haaz, 1998, Cancer Res, 58, 468
- Rajaonarison, 1992, Drug Metab Dispos, 20, 578
- Kumar, 1996, J Pharmacol Exp Ther, 277, 423
- Koudriakova, 1998, Drug Metab Dispos, 26, 552
- Chiba, 1996, Drug Metab Dispos, 24, 307
- Kerr, 1997, Clin Pharmacol Ther, 61, 147
- Cato, 1997, Drug Metab Dispos, 25, 1104
- Jordan, 1998, J Natl Med Assoc, 90, 622
- Tateishi, 1996, Anesth Analg, 82, 162
- Feierman, 1996, Drug Metab Dispos, 24, 932
- Labroo, 1995, Drug Metab Dispos, 23, 490
- Ekstrom, 1996, Drug Metab Dispos, 24, 955
- Antila, 1998, Int J Clin Pharmacol Ther, 36, 446
- Wienkers, 1996, J Pharmacol Exp Ther, 277, 982
- Fleishaker, 1996, J Pharmacol Exp Ther, 277, 991
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Pui, C.-H., Relling, M. V., & Downing, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra023001 · Cited by 1,185
Antifungal activity of silver nanoparticles against Candida spp.
Panáček, A., Kolář, M., Večeřová, R., Prucek, R., Soukupová, J., Kryštof, V., Hamal, P., Zbořil, R., & Kvítek, L. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.065 · Cited by 964
Cytochromes P450 and metabolism of xenobiotics
Anzenbacher, P., & Anzenbacherová, E. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000897 · Cited by 889
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Metadata
- Authors
- Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J.
- Affiliations
- Tufts University (US)
- Corresponding author
- Greenblatt, David J.
- Venue
- Clinical Pharmacokinetics
- Published
- 2000-02
- Volume
- 38
- Issue
- 2
- Pages
- 111-180
- ISSN
- 0312-5963 (ISSN-L)
- OpenAlex
- W2076565275
- Cited by
- 508
- References
- 537
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 4 · 2023: 8 · 2022: 10 · 2021: 10 · 2020: 17 · 2019: 8 · 2018: 11 · 2017: 7 · 2016: 17 · 2015: 15 · 2014: 14 · 2013: 15 · 2012: 19
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 34223, T32MH019924, MH-19924)
- National Institute on Drug Abuse (DA05258)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- antifungal agents, drug-drug interactions, drug metabolism, cytochrome P450 inhibition, CYP3A4, CYP2C9, CYP2C19, P-glycoprotein, ketoconazole, fluconazole, itraconazole, miconazole, terbinafine, sulfamethoxazole, cyclosporine, tacrolimus, phenytoin, warfarin, immunosuppression
- MeSH terms
- Animals, Antifungal Agents, Cytochrome P-450 Enzyme System, Drug Interactions, Pharmaceutical Preparations, Humans, Oxidation-Reduction, ATP Binding Cassette Transporter, Subfamily B, Member 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance. https://app.cochat.ai/papers/10.2165/00003088-200038020-00002
- The paper
- Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000). Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance. Clinical Pharmacokinetics. https://doi.org/10.2165/00003088-200038020-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.